Circulating Progranulin: A Promising Novel Diagnostic and Prognostic Biomarker in Canine Oncology.

IF 2.7 2区农林科学 Q1 AGRICULTURE, DAIRY & ANIMAL SCIENCE

Animals Pub Date : 2025-05-30 DOI:10.3390/ani15111605

Keon Kim, Yeong Jun Kim, Chang Hyeon Choi, Yoon Jung Do, Woong Bin Ro, Chang Min Lee

{"title":"Circulating Progranulin: A Promising Novel Diagnostic and Prognostic Biomarker in Canine Oncology.","authors":"Keon Kim, Yeong Jun Kim, Chang Hyeon Choi, Yoon Jung Do, Woong Bin Ro, Chang Min Lee","doi":"10.3390/ani15111605","DOIUrl":null,"url":null,"abstract":"Progranulin (PGRN) is a pluripotent growth factor that has shown promise as a diagnostic and prognostic biomarker for various neoplastic conditions in humans. This study aims to explore the PGRN as a novel biomarker for diagnosing and predicting the prognosis in canine tumors. Dogs (n = 104) with tumors as the chief complaint were selected and classified based on clinical categorization, malignancy, and metastasis. The control group (n = 30) consisted of healthy dogs with no evidence of neoplastic diseases. Serum PGRN levels were quantified using enzyme-linked immunosorbent assay (ELISA). Dogs with tumors exhibited significantly elevated PGRN levels compared to control dogs (p < 0.0001), with a high sensitivity of 90.91%. Malignant tumors demonstrated markedly higher PGRN levels relative to the control group (p = 0.0012), while no significant difference was found between benign tumors and the control group. Additionally, serum PGRN was identified as a significant marker for differentiating metastatic tumors from non-metastatic ones (p = 0.0264). PGRN exhibited high sensitivity for tumor detection, suggesting that it may serve as a screening biomarker. Prognostically, increased PGRN correlated with unfavorable outcomes, notably linked to malignancy and metastasis. This study underscores the potential of PGRN as a novel biomarker with early diagnostic and prognostic value in canine oncology.","PeriodicalId":7955,"journal":{"name":"Animals","volume":"15 11","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153816/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Animals","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3390/ani15111605","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AGRICULTURE, DAIRY & ANIMAL SCIENCE","Score":null,"Total":0}

引用次数: 0

Abstract

Progranulin (PGRN) is a pluripotent growth factor that has shown promise as a diagnostic and prognostic biomarker for various neoplastic conditions in humans. This study aims to explore the PGRN as a novel biomarker for diagnosing and predicting the prognosis in canine tumors. Dogs (n = 104) with tumors as the chief complaint were selected and classified based on clinical categorization, malignancy, and metastasis. The control group (n = 30) consisted of healthy dogs with no evidence of neoplastic diseases. Serum PGRN levels were quantified using enzyme-linked immunosorbent assay (ELISA). Dogs with tumors exhibited significantly elevated PGRN levels compared to control dogs (p < 0.0001), with a high sensitivity of 90.91%. Malignant tumors demonstrated markedly higher PGRN levels relative to the control group (p = 0.0012), while no significant difference was found between benign tumors and the control group. Additionally, serum PGRN was identified as a significant marker for differentiating metastatic tumors from non-metastatic ones (p = 0.0264). PGRN exhibited high sensitivity for tumor detection, suggesting that it may serve as a screening biomarker. Prognostically, increased PGRN correlated with unfavorable outcomes, notably linked to malignancy and metastasis. This study underscores the potential of PGRN as a novel biomarker with early diagnostic and prognostic value in canine oncology.

查看原文本刊更多论文

循环前颗粒蛋白：一种有前途的犬肿瘤诊断和预后生物标志物。

前颗粒蛋白（PGRN）是一种多能生长因子，有望作为人类各种肿瘤疾病的诊断和预后生物标志物。本研究旨在探索PGRN作为犬肿瘤诊断和预测预后的新型生物标志物。选择以肿瘤为主诉的狗（n = 104），并根据临床分类、恶性和转移进行分类。对照组（n = 30）由无肿瘤疾病证据的健康犬组成。采用酶联免疫吸附法（ELISA）定量测定血清PGRN水平。与对照犬相比，肿瘤犬的PGRN水平显著升高（p < 0.0001），灵敏度高达90.91%。恶性肿瘤患者PGRN水平明显高于对照组（p = 0.0012），良性肿瘤患者PGRN水平与对照组无显著差异。此外，血清PGRN被确定为区分转移性肿瘤和非转移性肿瘤的重要标志物（p = 0.0264）。PGRN对肿瘤检测具有较高的敏感性，提示其可作为一种筛选性生物标志物。预后方面，PGRN升高与不良预后相关，特别是与恶性肿瘤和转移有关。这项研究强调了PGRN作为一种具有犬肿瘤早期诊断和预后价值的新型生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Animals Agricultural and Biological Sciences-Animal Science and Zoology

CiteScore

4.90

自引率

16.70%

发文量

3015

审稿时长

20.52 days

期刊介绍： Animals (ISSN 2076-2615) is an international and interdisciplinary scholarly open access journal. It publishes original research articles, reviews, communications, and short notes that are relevant to any field of study that involves animals, including zoology, ethnozoology, animal science, animal ethics and animal welfare. However, preference will be given to those articles that provide an understanding of animals within a larger context (i.e., the animals'' interactions with the outside world, including humans). There is no restriction on the length of the papers. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental details and/or method of study, must be provided for research articles. Articles submitted that involve subjecting animals to unnecessary pain or suffering will not be accepted, and all articles must be submitted with the necessary ethical approval (please refer to the Ethical Guidelines for more information).